Mylan adds generic Detrol, HIV/AIDS drugs
Mylan Inc. said on Thursday that it had introduced a generic incontinence drug to the U.S. market and was selected by the South African government as a supplier of antiretroviral drugs.
Cecil-based Mylan has started selling Tolterodine Tartrate tablets, the generic version of Detrol, made by Pfizer Inc. Tolterodine Tartrate had U.S. sales of $61.5 million for the 12 months ended Sept. 30.
The company said the South African National Department of Health selected Mylan's Indian subsidiary to supply it with 31 percent of the 30 million units of HIV/AIDS drugs it will buy in a two-year period ending Dec. 31, 2014.
Mylan's share of the contract is valued at about $127.5 million.
Add Alex Nixon to your Google+ circles.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.